bioMérieux S.A.

Paris Stock Exchange BIM.PA

bioMérieux S.A. Free Cash Flow for the year ending December 31, 2023: USD 118.21 M

bioMérieux S.A. Free Cash Flow is USD 118.21 M for the year ending December 31, 2023, a -41.36% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

bioMérieux S.A. Free Cash Flow for the year ending December 31, 2022 was USD 201.58 M, a -66.88% change year over year.
bioMérieux S.A. Free Cash Flow for the year ending December 31, 2021 was USD 608.56 M, a 63.18% change year over year.
bioMérieux S.A. Free Cash Flow for the year ending December 31, 2020 was USD 372.95 M, a 145.44% change year over year.
bioMérieux S.A. Free Cash Flow for the year ending December 31, 2019 was USD 151.95 M, a -23.43% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Paris Stock Exchange: BIM.PA

bioMérieux S.A.

CEO	Mr. Pierre Boulud
IPO Date	July 7, 2004
Location	France
Headquarters	376 Chemin De l'Orme
Employees	13,409
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Key trends

Past 5 years